Exclusive Summary

• Fully off-patent with mature market awareness logically eliminating early educational costs, serving as a classic and indispensable intravenous therapy for hypertensive emergencies and perioperative care.
• Features a unique dual mechanism (peripheral alpha-1 blockade and central 5-HT1A agonism) for smooth blood pressure reduction without reflex tachycardia, strongly recommended by international guidelines like ESC as a first-line acute treatment.
• Backed by China's optimized injectable manufacturing and immense supply chain capacities, it provides global distributors with decisive cost advantages, lucrative margins for tender biddings, and ready CTD dossiers for rapid registration.